MedPath

Mater Research Initiates Trial for Novavax's Combined COVID-19 and Flu Vaccine

• Mater Research in Brisbane has begun a clinical trial for a combined COVID-19 and influenza vaccine developed by Novavax. • The protein-based, non-mRNA vaccine aims to protect individuals unable to receive mRNA vaccines by using a coronavirus spike protein segment to trigger an immune response. • The trial seeks 150 healthy participants over 65 who haven't received a flu vaccine in the past two months and will run for three weeks. • Researchers hope the combined vaccine option will increase vaccination rates against both influenza and COVID-19, addressing current under-vaccination trends.

Mater Research in Brisbane, Australia, has commenced a clinical trial evaluating a combined COVID-19 and influenza vaccine developed by Novavax. This initiative aims to provide a non-mRNA vaccine option for individuals who cannot receive mRNA vaccines, potentially boosting vaccination rates for both diseases.
The protein-based vaccine includes a segment of the coronavirus spike protein, designed to trigger an immune response by presenting a harmless piece of the protein to the immune system. This prompts immune cells to recognize the spike protein as a foreign invader and build a defense against it.

Trial Details and Objectives

The trial, set to run for three weeks after commencing on November 4, seeks 150 healthy participants over the age of 65 who have not received an influenza vaccine in the past two months. Mater Research’s Respiratory, Infectious Disease and Thoracic Oncology (RIO) Unit is managing the trial, which is one of over 20 clinical trials focused on respiratory health currently underway at the institute.
Professor Paul Griffin, Mater Infectious Diseases Director and the trial's principal investigator, noted the concerning trend of under-vaccination against both influenza and COVID-19. "We know that the majority of people are currently under-vaccinated against both influenza and Covid-19," he stated. "We hope that providing people with the option of an approved combination vaccine will help with vaccine uptake as there will be no need for two jabs."

Addressing Vaccine Hesitancy and Access

Professor Griffin also highlighted the importance of offering a non-mRNA option. "We know there are many people who cannot have or do not want to have an mRNA vaccine. Participating in this trial gives people access to a non mRNA option as part of the trial and will provide the data upon which a decision can potentially be made to approve them in the future."
The institute reported that in the past year, only 559,000 out of 5.56 million Queenslanders have received a COVID-19 vaccination. Influenza vaccinations have also decreased compared to the previous year’s free flu vaccination campaign, with 1.7 million vaccinations administered this year.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Novavax Resumes Clinical Trials for COVID-19 and Flu Combination Vaccine After FDA Clearance

The FDA has lifted a clinical hold on Novavax, allowing the company to resume trials for its COVID-19 and influenza combination vaccine (CIC) and standalone influenza vaccines.
The Phase III trial will assess the CIC vaccine's efficacy in adults aged 65 and older, comparing its immune response to standard vaccines.

Novavax Launches Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccines

Novavax has initiated a Phase 3 trial for its COVID-19-Influenza Combination (CIC) vaccine and stand-alone influenza vaccine, evaluating immunogenicity and safety.
The trial compares the CIC and stand-alone influenza vaccines to Novavax's updated COVID-19 vaccine and a licensed seasonal influenza vaccine in adults aged 65 and older.

FDA Lifts Clinical Hold on Novavax's COVID-19-Influenza Combination Vaccine Trials

The FDA has lifted the clinical hold on Novavax's Phase III trials for its COVID-19-influenza combination (CIC) vaccine and standalone influenza vaccine, allowing recruitment to resume.
The clinical hold was initiated due to a serious adverse event report of motor neuropathy in a Phase II trial participant, later reclassified as unrelated to the vaccine.

FDA Lifts Clinical Hold on Novavax's Flu Vaccine Trials After Adverse Event Review

The FDA has lifted the clinical hold on Novavax's Phase 3 trial for its combination COVID-19 and influenza vaccine, as well as its standalone flu shots.
The hold was initiated following a serious adverse event of motor neuropathy in a Phase 2 trial participant, which has now been reclassified as ALS and deemed unrelated to the vaccine.

Clinical Trial Underway for Novel RSV and hMPV Vaccine in Older Adults

A Phase I clinical trial is recruiting older adults to assess the safety and immunogenicity of a new vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).
The vaccine candidate, developed by Vicebio using the University of Queensland's molecular clamp technology, aims to reduce the burden of respiratory illnesses in vulnerable populations.

Phase 3 Trial Aims to Combat Norovirus with mRNA Vaccine in Adults

A Phase 3 clinical trial, Nova 301, is underway to evaluate an investigational mRNA vaccine's efficacy against norovirus in adults aged 18 and older.
The trial seeks to enroll approximately 25,000 participants globally, comparing the investigational vaccine to a placebo jab over a 25-month period.

South West Researchers Launch Trial for Improved Flu Vaccine in Older Adults

Researchers in the South West are seeking participants for a clinical trial evaluating a new influenza vaccine designed to enhance protection in older adults.
The trial aims to assess the efficacy of the investigational vaccine in reducing the risk of serious flu-related illness, potentially alleviating pressure on healthcare services during winter.

Richmond Clinical Trials Seeks Volunteers for RSV and Norovirus Vaccine Studies

Richmond Clinical Trials is recruiting participants aged 19 and older with managed conditions like asthma, COPD, or diabetes for vaccine studies.
The trials aim to develop a combination vaccine for RSV and hMPV, viruses impacting lung health, and a vaccine against Norovirus, a highly contagious gastrointestinal virus.

Doherty Clinical Trials to Conduct Phase I Trial of Needle-Free Avian Influenza Vaccine

Doherty Clinical Trials initiates a Phase I clinical trial for a needle-free avian influenza vaccine developed by Vaxxas, assessing its safety and tolerability.
The trial utilizes Vaxxas' High-Density Microarray Patch (HD-MAP) technology, delivering the vaccine to immune cells just below the skin surface.

Reference News

[1]
Mater Research initiates combined Covid-flu vaccine trial
clinicaltrialsarena.com · Oct 14, 2024

Mater Research in Brisbane has started a clinical trial for a Novavax protein-based Covid-19 and flu vaccine for individ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy